Compare KeyCorp (KEY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Sana Biotechnology Inc — how do they compare? KeyCorp trades at $22.7 (market cap $24.32B), while Sana Biotechnology Inc trades at $3.78 (market cap $1.13B). The key difference: KeyCorp is far larger — about 21.5× Sana Biotechnology Inc's market cap, and KeyCorp pays a 3.61% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KEY | SANA | |
|---|---|---|
Market Cap | $24.32B | $1.13B |
Sector | Financials | Health |
52-Week High | $23.99 | $5.92 |
52-Week Low | $16.78 | $2.68 |
Dividend Yield | 3.61% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $22.68, down 0.22% on the day, with a bearish technical signal but strong fundamental recovery. The company reported Q2 2026 EPS of $0.44, beating estimates, and shows robust revenue growth to $7.29B in 2025. Recent expansion includes the acquisition of Clearwater UK, enhancing its investment banking footprint.
The outlook is positive with a consensus price target of $29.41, representing significant upside. Risks include economic uncertainty impacting loan growth and net interest income. The stock offers a dividend yield supported by consistent payouts, with analyst sentiment strongly favoring a buy rating.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
